Advisors Preferred’s Jazz Pharmaceuticals JAZZ Stock Holding History

Advisors Preferred’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-26,790	Closed	-$2.92M	–	241
2024 Q3	$2.92M	Buy	+26,790	New	+$2.94M	0.45%	58

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advisors Preferred's JAZZ Position: Q4 2024 in Review

Advisors Preferred sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 26,790 shares — an estimated $2.92M sold.

Advisors Preferred first reported a position in JAZZ in Q3 2024 and held it in 1 quarter. The position peaked at $2.92M in Q3 2024. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

Advisors Preferred reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Advisors Preferred sold 26,790 Jazz Pharmaceuticals shares in Q4 2024, an estimated $2.92M.
Advisors Preferred first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Advisors Preferred's Jazz Pharmaceuticals position peaked at $2.92M in Q3 2024.
508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Advisors Preferred's 13F filing for Q4 2024, filed 28 Jan 2025.